Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 4/20 | 1.00 |
| ▸ | MTOR | P42345 | 4/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 3/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 3/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 3/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 2/20 | 1.00 |
| ▸ | PIK3C2A | O00443 | 2/20 | 1.00 |
| ▸ | PRKDC | P78527 | 2/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 1.00 |
| ▸ | CHUK | O15111 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | PIK3C2G | O75747 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | BRAF | P15056 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pi-103 SCHEMBL30387212 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| Pi-103 SCHEMBL258242 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| Pi-103 SCHEMBL29352781 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| Pi-103 SCHEMBL29929906 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| Pi-103 SCHEMBL29527390 | 0.99 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| SCHEMBL10092301 | 0.91 | PIK3CA (0.83) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| SCHEMBL30538318 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| SCHEMBL13976099 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| SCHEMBL10092326 | 0.88 | PIK3CA (0.79) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| SCHEMBL10112597 | 0.88 | PIK3CA (0.79) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059689-A1 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF PHARYNGEAL FOREGUT ENDODERM AND ITS DERIVATIVES | UNIVERSITY OF MASSACHUSETTS (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-113667747-B | Method for treating oral cancer | 长庚大学 | 2025-01-24 | — | — | CN | disclosed |
| EP-4387667-A1 | COMBINATION RADIOTHERAPY | Telix Pharmaceuticals (Innovations) Pty Ltd (AU) | 2024-06-26 | — | — | EP | disclosed |
| EP-4274593-A1 | SENECA VALLEY VIRUS COMBINATION THERAPY TO TREAT A CANCER REFRACTORY TO A CHECKPOINT INHIBITOR | Seneca Therapeutics, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023019308-A1 | COMBINATION RADIOTHERAPY | Telix International Pty Ltd (AU) | 2023-02-23 | — | — | WO | disclosed |
| CN-115645534-A | Novel compositions and methods for treating or preventing skin disorders | 德雷克塞尔大学 | 2023-01-31 | — | — | CN | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115414480-A | Dianhydrogalactitol in combination with radiation for treatment of non-small cell lung cancer and glioblastoma multiforme | 德玛医药 | 2022-12-02 | — | — | CN | disclosed |
| WO-2022150769-A1 | SENECA VALLEY VIRUS COMBINATION THERAPY TO TREAT A CANCER REFRACTORY TO A CHECKPOINT INHIBITOR | SENECA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-11351209-B2 | Inhibitors of PI3K p-delta 110 for use in delivery of viruses in the treatment of cancer | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2022-06-07 | — | — | US | disclosed |
| EP-3999087-A1 | SECOND GENERATION SENECA VALLEY VIRUS ONCOLYTIC THERAPY: COMPOSITIONS AND METHODS THEREOF | The Trustees of Columbia University in the City of New York (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351209-B2 | Inhibitors of PI3K p-delta 110 for use in delivery of viruses in the treatment of cancer | PI4KA, PIK3CA, PIK3R4 | PIK3CA 2/4885PIK3CG 7/4885MTOR 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.